Outcome of patients with ELN22 favorable-risk AML. (A) Outcome of patients with NPM1 mutations, patients with CBF leukemia and patients with CEBPA bZIP in-frame mutations within the ELN22 favorable risk category. (B) Outcome of patients with ELN22 favorable-risk AML with or without MR gene comutations (ie, mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2). (C) Outcome of patients with ELN22 favorable-risk AML with or without MR gene comutations, stratified by age (≤/>60 years). (D) Outcome of patients with ELN22 favorable-risk NPM1-mutated AML with or without MR gene mutations. mut, mutated.